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Reactivation of Latent Human Cytomegalovirus
by Allogeneic Stimulation of Blood Cells
from Healthy Donors
Cecilia SoÈ derberg-NaucleÂ r,* Kenneth N. Fish, Several animal models have been established to un-
derstand mechanisms involved in latency and reactiva-and Jay A. Nelson²
tion of CMV (Hamilton and Seaworth, 1985; Bruning etDepartment of Microbiology and Immunology
al., 1986; Yagyu et al., 1993; Reddehase et al., 1994). InOregon Health Sciences University
murine organ transplant models, reactivation of murinePortland, Oregon 97201-3098
cytomegalovirus (MCMV) was shown to be influenced
by the state of immunosuppression and histoincompati-
bility between the donor and the recipient (Hamilton and
Summary Seaworth, 1985; Bruning et al., 1986; Yagyu et al., 1993;
Reddehase et al., 1994). In MCMV latently infected mice,
Reactivation of human cytomegalovirus (HCMV) re- the spleen, kidneys, and bone marrow were shown to
sults in severe disease in AIDS patients and immuno- be important sources of virus (Olding et al., 1975; Jordan
compromised patients receiving blood transfusions or and Mar, 1982; Mercer et al., 1988). Activation of virus
organ or bone marrow grafts. Although the site of in latently infected animals has been shown to occur
HCMV latency is unknown, blood cells have been im- through either intraperitoneal injection of thioglycollate
plicated as a viral reservoir. In this study, we demon- (Pollock et al., 1997) or allogeneic stimulation (Schmader
strate HCMV reactivation in vitro from seven consecu- et al., 1992). The peripheral blood of latently infected
tive healthy donors through allogeneic stimulation of animals was also demonstrated to be a reservoir of virus
peripheral blood mononuclear cells (PBMCs). HCMV since allogeneic stimulation resulted in the activation of
replication was detected at 17 days poststimulation, MCMV replication (Olding et al., 1975; Schmader et al.,
and virus was recovered after long-term culture from a 1992). Although the identification of the cell type remains
macrophage expressing dendritic cell markers. Thus, controversial, the above studies have suggested that T
these observations demonstrate that PBMCs harbor cells, B cells, or macrophages may be potential sites
latent HCMV, which reactivates in a myeloid lineage for viral latency (Olding et al., 1975; Jordan and Mar,
cell upon allogeneic stimulation. 1982; Mercer et al., 1988; Stoddart et al., 1994; Koffron
et al., 1995; Pollock et al., 1997).
In humans, examination of organ tissues and periph-Introduction
eral blood obtained from patients with HCMV disease
has suggested that peripheral blood mononuclear cellsHuman cytomegalovirus (HCMV) is a ubiquitous patho-
(PBMCs) are a viral reservoir (Chou, 1986; Meyers, 1986;gen that is the major cause of morbidity and mortality
Gnann et al., 1988; Tegtmeier, 1989; Taylor-Wiedemanin immunocompromised individuals, such as transplant
et al., 1991). Further analyses of separated PBMC popu-and AIDS patients, as well as a leading cause of congeni-
lations obtained from HCMV-seropositive donors havetal birth defects (Britt and Alford, 1996). HCMV is also
identified monocytes as the predominant infected cellassociated with the development of atherosclerosis, re-
type (Taylor-Wiedeman et al., 1991). While HCMV infec-stenosis after coronary angioplasty, chronic rejection in
tion of monocytes was found to be infrequent and viralorgan transplant patients (Grattan et al., 1989; Melnick
replication restricted to early events of gene expressionet al., 1995; Zhou et al., 1996), and chronic graft-versus-
(Ibanez et al., 1991), examination of organ tissues earlyhost disease in bone marrow transplant patients (LoÈ nn-
in HCMV disease has demonstrated extensive viral geneqvist et al., 1984; SoÈ derberg et al., 1996). Most individu-
expression in tissue macrophages (Gnann et al., 1988;als become infected with HCMV early in life, and de-
Sinzger et al., 1996). These observations suggested thatpending on the geographic location, between 60% and
macrophage differentiation is a prerequisite for produc-100% of adults are carriers of the virus (Britt and Alford,
tive HCMV infection.1996). Similar to other herpesviruses, HCMV establishes
CD141 monocytes in the peripheral blood are termi-lifelong latency in thehost after a primary infection that is
nally differentiated cells derived from myeloid/granulo-characterized by persistence of the viral genome without
cyte precursors. In vivo, stimulation of monocytes bythe production of infectious virus. The respective sites
contact with T and B cells during antigen processingof latency for other herpesviruses such as Epstein-Barr
events induces differentiation of monocytes into macro-and herpes simplex viruses are B cells and neurons
phages for function as immune effector cells. A variety(Kieff 1996; Roizman and Sears, 1996). However, al-
of tissue culture protocols has been established tothough transmission of latent HCMV has been shown
mimic the in vivo development of monocyte-derivedto occur through transfusion of blood products, bone
macrophages (MDMs), which includes treatment ofmarrow grafts, and solid organs (Chou, 1986; Meyers,
monocytes with cytokines, mitogens, corticosteroids,1986; Tegtmeier, 1989; Britt and Alford, 1996), the iden-
or lipopolysaccharide (LPS) (reviewed by Adams andtity of cells harboring latent or persistent virus is un-
Hamilton, 1992). MDMs derived by these methods haveknown.
successfully been utilized for the in vitro propagation of
a number of macrophage-tropic viruses (Gendelman et
al., 1988; Schrier et al., 1990; Matloubian et al., 1993).*Present address: Department of Biosciences, Karolinska Institute,
In contrast, culture of HCMV in MDMs has proven to beNovum, BlickagaÊngen 6, 141 57 Stockholm, Sweden.
²To whom correspondence should be addressed. more difficult, often resulting in abortive infection (Rice
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Table 1. Characterization of Donor Pairs Used for Allogeneic Reactivation of HCMV
Donor pair A B C D E F G H H9a
Donors 1/2 3/4 5/6 7/8 9/10 11/12 13/14 15/16 15/16
Serologyb 2/1 1/2 2/2 1/2 1/1 2/2 2/2 2/1 2/1
DNAc 1/1 1/2 1/2 1/2 1/1 ND ND ND ND
Infectious Virusd 54 46 46 26 26 Ð Ð 61 57
(Days poststimulation)
a Donor pair H9 represents donor pair H at a secondary blood donation obtained 4 months after the first donation.
b The presence of HCMV antibodies (1) in each individual was determined by a standard ELISA assay used at OHSU.
c The presence of HCMV DNA was determined by PCR analysis (Soderberg et al., 1993).
d The presence of infectious virus was determined by cocultivation of sonicated Allo-MDM with human fibroblasts (HF).
The first time point at which infectious virus was detected in Allo-MDM inoculated HF is indicated for each donor pair.
et al., 1984; Taylor-Wiedeman et al., 1994). These obser- also observed at day 17 in 4 of 5 cultures. Interestingly,
in one donor pair (donor pair B) the expression of pp150vations suggested that HCMV utilizes a selective MDM
differentiation pathway to produce virus. Our group has was not detected until 54 days post±allogeneic stimula-
tion (Figure 1B). Consistent with HCMV RNA expression,established an MDM differentiation system that relies on
the mitogenic stimulation of PBMCs to generate HCMV the IE protein and the late protein gB were detected in
adherent cells between days 17 and 60 poststimulationpermissive macrophages (Ibanez et al., 1991). Although
macrophages differentiated by this method are suscep- (Figure 2). Failure to detect HCMV transcripts and pro-
tein in the Allo-MDMs at day 10 in all donor pairs indi-tible to in vitro infection, attempts to reactivate HCMV
from PBMCs obtained from latently infected individuals cates that the virus is latent and not persistent in this
cell population. The frequency of Allo-MDMs containinghave been unsuccessful using this method or others
(Taylor-Wiedeman et al., 1994). HCMV proteins was 1±12 of 1000 (0.1%±1.2%) when
viral antigens were first detected in each culture (FigureIn this study, we demonstrate reactivation of HCMV in
long-term cultures of allogeneically stimulated adherent 2B). By day 60, poststimulation, between 2% and 25%
of the cells expressed HCMV proteins in the differentmonocyte-derived macrophages (Allo-MDMs). Infec-
tious virus was recovered from a myeloid lineage cell Allo-MDM cultures. The high number of infected cells
in some of the cultures at this interval most likely reflectsphenotype that expressed both macrophage and den-
dritic cell markers.These observations provide evidence infection of uninfected Allo-MDMs with reactivated virus
in vitro.that HCMV establishes a true latent state in myeloid
lineage cells in the peripheral blood, which reactivates To demonstrate the presence of infectious virus in
Allo-MDMs, cells obtained from HCMV-positive donorupon allogeneic stimulation.
pair cultures were collected every 7±10 days for up to
90 days poststimulation. Cell samples were sonicatedResults
and plated onto HF, and HF infection was verified by
immunofluorescence for HCMV IE. Infectious virus wasAllogeneic Reactivation of Latent HCMV
in Macrophages Obtained from demonstrated by this method in 5 of 5 of the Allo-MDM
cultures at days 26±61 poststimulation (Table 1). In con-Healthy Blood Donors
Since HCMV frequently reactivates in recipients of allo- trast, when Con A-MDMs were derived from the same
individual donors by mitogenic stimulation of PBMCs,geneic blood transfusions or organ or bone marrow
transplants, we examined whether virus could be reacti- virus could not be detected for up to 90 days poststimu-
lation (data not shown). Interestingly, HCMV reactivationvated from its latent state in allogeneically stimulated
PBMCs obtained from naturally infected healthy blood was observed in Allo-MDMs obtained from two HCMV-
seronegative donors (donor pair C). However, one ofdonors. PBMCs from healthy donors were tested for
HCMV exposure by ELISA for serum antibodies and by these donors was HCMV DNA positive, which is consis-
tent with the recovery of virus from this donor pair (TablePCR for the presence of HCMV DNA in PBMCs (Table
1). Allogeneically stimulated cell cultures were estab- 1). The successful reactivation of HCMV in the Allo-
MDMs but not in the Con A-MDMs from the same donorslished by mixing PBMCs from histoincompatible donor
pairs. After 48 hr of allogeneic stimulation, nonadherent implies a fundamental difference in the differentiation
process of PBMCs.cells were removed from the culture, and Allo-MDMs
were maintained with feeding every 4 days for up to 90 Long-term virus isolation cultures were established
from HF cells inoculated with sonicates of Allo-MDMsdays (Figure 1A). Cell samples were collected from these
cultures at the indicated intervals and evaluated for obtained from different donor pairs to allow recovery
and characterization of reactivated infectious HCMVHCMV gene expression by RT-PCR. The presence of
HCMV-specific proteins in the Allo-MDMs was detected strains. CPE was observed in HF cells infected with cell
sonicates from 6 of 7 donor pairs after 10±16 weeks inby immunofluorescence, and virus production was as-
sessed by coculture of sonicated cell samples with hu- culture. Reactivated HCMV strains obtained from the
Allo-MDMs replicated slowly in HF and were extremelyman fibroblasts (HF). HCMV immediate early (IE) RNA
was first detected at day 17 poststimulation in 5 of 5 cell-associated, similar to HCMV isolates obtained from
acutely infected individuals (data not shown). Restric-allogeneically stimulated cultures (Figure 1B). A tran-
script encoding a late tegument protein, pp150, was tion enzyme analyses were performed on HCMV DNA
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Figure 2. HCMV Protein Expression in Allo-MDMs with Reactivated
Virus
The expression of the HCMV IE and gB proteins in Allo-MDMs with
reactivated virus was determined by immunofluorescence as de-
scribed in Experimental Procedures. (A) illustrates a representative
example of the presence of IE (red) and gB (green) in Allo-MDMs
by double-label immunofluorescence with confocal microscopy. (B)
indicates the temporal expression and the frequency of cells ex-
pressing HCMV IE and gB at the indicated time points. A minimum
Figure 1. HCMV RNA Expression in Allo-MDMs with Reactivated
of 1500 cells was counted for each time point.
Virus a The expression of HCMV IE86 and gB (IE86/gB) was determined
(A) A phase microscopy photo of Allo-MDMs at 14 days poststimula- by immunofluorescence (Fish et al., 1995) in fixed Allo-MDMs at the
tion (magnification, 80.33). indicated intervals.The numberof positive cells per 1000 Allo-MDMs
(B) Temporal expression of IE and pp150 RNA in Allo-MDMs ob- is shown at the indicated time points.
tained from all the donor pairs. The expression of HCMV IE and of
the late pp150 RNA was determined in Allo-MDMs at different time
points after allogeneic stimulation. Both HCMV DNA PCR and RT- clearly demonstrate the unique genotype of the reacti-
PCR analysis were performed as described in the Experimental vated virus strains.
Procedures. HCMV DNA but not RNA was detected in the donors
at the time for blood donation (Table 1). Cell samples were collected
HCMV Reactivates in a Macrophage Expressingat the indicated time points by scraping, and DNA and RNA were
Dendritic Cell Markersprepared as described. PCR analysis was performed on DNA or
cDNA samples. The band sizes and the temporal expression of To identify the cell type that reactivated HCMV, Allo-
HCMV IE and pp150 RNA were demonstrated by direct gel analysis MDMs were analyzed by flow cytometry for the expres-
on a 1% agarose gel. HCMV IE and pp150 RNA were detected in sion of specific cell surface markers expressed on T
all tested donor pairs at 17 days poststimulation, but not at the time and B cells, NK cells, myeloid cells, and dendritic cells.
for blood donation or at 10 days post±allogeneic stimulation.
Control analyses were performed with fresh monocytesa The expression (1) of HCMV IE or pp150 RNA (IE/pp150) was
and with dendritic cells generated by stimulation ofdetermined by RT±PCR analysis. For each donor pair, samples were
assessed for the presence of these viral RNAs at the indicated monocytes with recombinant IL-4 and GM-CSF (Sallusto
intervals. and Lanzavecchia, 1994). Cells staining for T, B, and NK
cell markers were absent from the adherent cell fraction
of Allo-MDM cultures (data not shown). The Allo-MDMs
demonstrated a uniform surface expression of the mono-from HF cells infected with reactivated virus to deter-
mine the genotype of each isolate. A representative cyte/macrophage markers CD14 and CD64 (Figure 4A).
Surprisingly, expression of the dendritic cell markersexample of the restriction enzyme analysis of virus reac-
tivated from donor pair H obtainedfrom twoconsecutive CD1a and CD83 was also observed. Colocalization of
both CD14 and CD83 was observed on Allo-MDMsexperiments (H and H9) is shown in Figure 3. This figure
demonstrates that the sizes of the fragments obtained throughout the experimental time course as demon-
strated by double label flow cytometric analysis (Figurefrom digestion of the H and H9 isolates with HindIII or
EcoRI are identical. Furthermore, the restriction enzyme 4B). In contrast, control dendritic cells expressed CD1a
and CD83 but were negative for CD14 as previouslyanalyses also demonstrate that the reactivated virus
isolates are distinct from the laboratory isolates AD169 reported (Sallusto and Lanzavecchia, 1994). High levels
of HLA class II (Figure 4A), HLA class I, CD13, VCAM-1,and Towne as well as an isolate obtained from a patient
with acute HCMV disease (Po). These experiments ICAM-1, and CD40 were observed on the Allo-MDMs
Cell
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Figure 4. Analysis of the Allo-MDM Phenotype, which ReactivatesFigure 3. Restriction Enzyme Analysis of Allo-MDM Reactivated
HCMV HCMV
Flow cytometric analysis was performed on the Allo-MDMs to deter-Restriction enzyme analysis was performed with Allo-MDM reacti-
vated HCMV genomic DNA. Reactivated virus recovered through mine the phenotype of the cell reactivating HCMV. In these experi-
ments, antibodies directed against the macrophage markers CD14cocultivation of cell sonicates of Allo-MDMs with HF cells as well
as a clinical isolate, AD169, and Towne viral strains were grown and CD64 as well as the dendritic cell markers CD83 and CD1a,
antibodies to HLA class II, and an isotype control were used forand harvested as described in the Experimental Procedures. Ten
micrograms of total DNA from uninfected or the HCMV-infected analysis. In (A), flow cytometric analysis of Allo-MDMs (solid histo-
grams) demonstrates that the Allo-MDMs express both dendriticHF cells was digested with EcoR1 or HindIII, before Southern blot
analyses using 32P-labeled HCMV cosmid clones pCM1049 (A) and cell markers CD83 and CD1a as well as the monocyte/macrophage
markers CD14 and CD64 at 8 days postinfection. In contrast, den-pCM1058 (B) (as described in the Experimental Procedures). A rep-
resentative example of donor strain H and a strain isolated from the dritic cells (open histograms) expressed CD83, but not CD14. (B)
represents an example of flow cytometric analysis of Allo-MDMs atsame donor pair 4 months later (H9) demonstrate identical restriction
patterns, whereas unique restriction patterns were observed in the 14 days poststimulation,which demonstrates colocalization of CD14
and CD83 on cells.other HCMV strains.
as well as on monocytes and dendritic cells (data not
shown). The pattern of expression of these markers was studied for decades by many groups, the latent cellular
consistent in Allo-MDMs obtained from the different do- reservoir has been difficult to identify. The experiments
nor pairs. described in this study conclusively identify PBMCs as
An antibody to HCMV was utilized in combination with a cellular reservoir for HCMV latency and describe con-
antibodies to dendritic and macrophage antigens by ditions allowing reactivation of latent virus from naturally
double-label immunofluorescence confocal microscopy infected cells. First, we have demonstrated that PBMCs
to confirm the cellular origin of virus. Cells obtained from from naturally infected individuals contain HCMV geno-
donor pair A expressed HCMV IE as well as CD83 and mic DNA, which is inactive and does not produce infec-
CD14 at day 28 poststimulation (Figure 5) but were uni- tious virus. Second, we have shown that a specific cellu-
formly negative for HCMV antigens at day 26 poststimu- lar differentiation pathway is required to induce viral
lation (Figure 2B). Thus, the cells harboring reactivated expression and produce infectious virus from latently
virus expressed both CD14 and CD83. The above obser-
infected PBMCs. This pathway involves the allogeneic
vations provide the first evidence that a myeloid lineage
stimulation of PBMCs, which results in the reactivation
cell in the peripheral blood of healthy individuals is the
of latent HCMV in a macrophage expressing dendriticsource of latent HCMV, which, upon allogeneic stimula-
cell markers.tion, reactivates infectious virus. Since CD141 cells rep-
We have previously demonstrated that HCMV repli-resent approximately 10% of total PBMCs, detection of
cates in Con A-MDMs upon in vitro infection (Ibanez etvirus in 1±12 cells of 1000 Allo-MDMs implies a fre-
al., 1991; Fish et al., 1995). However, mitogenic stimula-quency of HCMV latently infected PBMCs of 0.01%±
tion of PBMCs was insufficient to reactivate HCMV from0.12%.
naturally infected cells. In the present study, we demon-
strate that allogeneic stimulation of naturally infectedDiscussion
PBMCs results in reactivation of latent virus. In addition,
the ability of Allo-MDMs but not Con A-MDMs to reacti-HCMV Replication in Macrophages Is Dependent
vate HCMV suggests that a specific monocyte-macro-on the State of Differentiation
phage differentiation pathway is induced by the alloge-This study describes HCMV reactivation from normal
donor blood cells in vitro. Although HCMV has been neic reaction between T cells and monocytes. Thus, the
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of myeloid progenitor cells results in production of infec-
tious HCMV after differentiation into CD141 macro-
phages. Transcripts associated with the lack of in-
fectious virus, which the authors suggest encode a
protein(s) important for viral latency, were detected in
the myeloid progenitor cells. However, we were not able
to detect the presence of these RNAs in Allo-MDMs
prior to activation of virus at day 17 poststimulation
(data not shown). While CD331 myeloid progenitor cells
would be an obvious site for HCMV latency, conclusive
identification of an in vivo latent site requires reactiva-
tion of virus from cells obtained from healthy individuals.
The hypothesis that CD331 myeloid progenitor cellsFigure 5. HCMV Reactivates in CD141 and CD831 Myeloid Lineage
may be a latent site of HCMV does not preclude theCells
existence of other reservoirs for virus, such as stromalDouble label immunofluorescence with an antibody against HCMV
IE (red) and the macrophage marker CD14 or the dendritic marker cells in the bone marrow microenvironment (Myerson
CD83 demonstrating the presence of HCMV in Allo-MDMs with these et al., 1984; Sinzger et al., 1993). For example, virus is
cellular markers. commonly isolated from bone marrow stroma in patients
with HCMV disease as well as in stromal cells infected
with HCMV in vitro (Simmons et al., 1990; Torok-Storb
recovery of HCMV from allogeneically stimulated cells et al., 1992). Thus, myeloid progenitor cells or mono-
would suggest that viral production is intimately linked cytes may also acquire HCMV through interactions with
to the activation of the immune system. persistently infected stromal cells in the bone marrow.
The Importance of Immune ActivationMyeloid Lineage Cells Are Reservoirs
of Latent HCMV in the Reactivation of HCMV
HCMV is an important cause of morbidity and mortalityMyeloid cells would provide an ideal site of latency for
a virus that is closely linked to the immune system for in transplant patients and AIDS patients. Thus, experi-
mental evidence for allogeneic reactivation of HCMVactivation. Since monocytes in the peripheral blood are
terminally differentiated cells with a short half-life, the from the peripheral blood of healthy donors has impor-
tant clinical implications. While control of HCMV replica-ability to reactivate latent HCMV in macrophages from
all the donor pairs tested implies that HCMV is main- tion is generally well managed by the immune system
in immunocompetent individuals, HCMV reactivationtained in a precursor population of the myeloid cell lin-
eage. The Allo-MDMs, which reactivated latent HCMV within the blood or donor organ in immunocompromised
patients frequently results in profound disease. Sinceupon allogeneic stimulation, were esterase positive and
expressed both macrophage (CD14 and CD64) and den- blood transfusion is commonly performed over histoin-
compatibility barriers, reactivation of HCMV through al-dritic cell markers (CD83 and CD1a). CD14 and CD83
double positive cells have previously been reported as logeneic stimulation of PBMCs would be expected if
either the donor or the recipient were virus positive.a transient cell phenotype during the differentiation of
CD341 hematopoietic progenitor cells stimulated with Equally important is the clinical relevance of the alloge-
neic reactivation of HCMV for organ and bone marrowIL-4 and GM-CSF (Caux et al., 1996), but whether these
cells are an intermediate cell phenotype between mac- transplant patients. HCMV infection has been implicated
in acute rejection in organ transplant patients and acuterophages and dendritic cells is unclear. Macrophages
that express dendritic cell markers may constitute reser- graft-versus-host disease in bone marrow transplant pa-
tients (BostroÈ m et al., 1990). The allogeneic activation ofvoirs for viruses other than HCMV. For example, cells
coexpressing the macrophage marker CD68 and the cells insolid organsor bone marrow grafts may provide a
microenvironment conducive to cellular differentiationdendritic cell marker CD83 were recently found to be
infected by the Kaposi's sarcoma±associated herpesvi- and reactivation of HCMV. In the present study, we dem-
onstrate that immune activation of myeloid-lineage cellsrus, human herpesvirus 8 (HHV-8), in the bone marrow
of multiple myeloma patients (Rettig et al., 1997). through allogeneic stimulation by T cells provides an
immunologic stimulus that facilitates reactivation ofHCMV has previously been reported to infect CD341
pluripotent stem cells both in vitro (Maciejewski et al., HCMV. Thus, the allogeneic activation of residual in-
fected leukocytes in the solid organ or bone marrow1992; Minton et al., 1994; Movassagh et al., 1996) and
in vivo (von Laer et al., 1995a; Mendelson et al., 1996). recipient tissue may be the primary mechanism of viral
activation in transplant patients.Furthermore, iatrogenicHowever, these findings are controversial and do not
explain why virus is not consistently found in all mature immunosuppression in the transplant setting would ex-
acerbate the severity of HCMV disease. Interestingly,peripheral cell lineages (Schrier et al., 1985; SoÈ derberg
et al., 1993; Brytting et al., 1995; von Laer et al., 1995b). transplant patients commonly reactivate HCMV be-
tween 1 and 4 months posttransplantation (MandanasA recently established culture system demonstrating
HCMV infection of CD331 myeloid progenitor cells in et al., 1996), which correlates with the time interval re-
quired to reactivate infectious virus by allogeneic stimu-vitro suggests that myeloid cells may be infected early
during hematopoiesis (Kondo et al., 1994, 1996). In this lation of PBMCs from healthy individuals in vitro. In
addition, initiation of an immune response by othermodel, the authors demonstrate that in vitro infection
Cell
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cellular proteins utilized immunofluorescence in combination withpathogens may also result in reactivation of latent virus.
confocal microscopy as described under immunocytochemistry.This situation is exemplified by the increased incidence
of HCMV disease following bacterial infections in differ-
Immunocytochemistry
ent groups of patients (DoÈ cke et al., 1994; van den Berg HCMV infected± and mock infected±MDM cultures grown in 8-well
et al., 1996) as well as in HIV-infected individuals who chamber slides or in Primaria 96-well plates were collected at differ-
experience other opportunistic infections. ent time points after infection. The cells were washed in PBS and
fixed in phosphate-buffered 1% paraformaldehyde (PFA) or metha-In summary, our observations provide evidence that
nol/acetone (1:1) for 10 min at room temperature and permeabilizeda myeloid lineage cell harbors truly latent HCMV, which
with 0.3% Triton X-100 in PBS. Cells were blocked with 10% normalcan be reactivated to produce infectious virus upon allo-
goat serum or 10% human AB serum in PBS for 30 min at room
geneic stimulation of PBMCs. Moreover, the cell pheno- temperature, and thereafter with antibodies against different HCMV
type that reactivated latent virus was identified as a gene products in a 1:100 dilution for 1±6 hr at room temperature,
macrophage expressing dendritic cell markers. Impor- antibodies against the major immediate early protein (rabbit-anti-
MIE [Stenberg et al., 1989]), or gB (mouse-anti-gB [UL55]). Bothtantly, our study describes an in vitro system that can
murine monoclonal antibodies were a kind gift from Dr. William Brittbe used to identify mechanisms involved in the main-
at the University of Alabama, Birmingham, AL. (Britt and Vugler,tenance of HCMV latency and to explore the cellular
1992). Cells were washed three times in PBS and binding of the
activation pathways that mediate HCMV reactivation. primary antibody was detected with a fluorescein isothiocyanate-
Furthermore, this cell culture system will provide an im- tetramethyl (FITC) conjugated goat anti-mouse or goat anti-rabbit
portant tool to examine mechanisms of HCMV immuno- antibody for 1±2 hr at room temperature. Double immunocytochem-
istry for cell surface markers was performed on live cells beforelogical surveillance as well as therapeutic approaches
fixation and staining for the HCMV IE antigen was performed.to prevent viral reactivation.
Stained cells were washed in PBS and mounted in Slow fade Anti-
fade Kit (Molecular Probes Inc., Eugene, OR) to ensure minimal
Experimental Procedures fluorescence fading. Fluorescence-positive cells were visualized on
an upright or inverted Leitz fluorescent microscope and the number
Establishment of Allogeneically Stimulated PBMC Cultures of infected cells was counted.
PBMCs were isolated from blood samples of 16 healthy blood do-
nors by density gradient centrifugation on Histopaque (Sigma Chem- Flow Cytometric Analyses of Allo-MDMs
ical Co.) as previously described (Fish et al., 1995). Subsequently, Afluorescence-activated cellanalyzer (FACSCalibur; Becton Dickin-
PBMCs were resuspended in Iscove's complete medium containing son) was used for all analyses of cell surface expression using
penicillin (100 IU/ml), streptomycin (100 mg/ml, both from GIBCO monoclonalantibodies directed against the following cell phenotype
Laboratories), and 10% human AB serum (Sigma). For allogeneic markers: CD4, CD8, CD19, CD56, CD13, CD14, CD64, CD1a, CD83,
stimulation experiments, equal numbers of cells from two different HLA class I molecules, HLA class II molecules, CD40, VCAM-1, and
blood donors at a cell concentration of 1.8 3 107 cells/ml were ICAM-1. Mean fluorescence values were obtained from histograms
mixed before plating on Primaria dishes (Becton Dickinson). After displaying the log fluorescence of FITC (FL1) or phycoerythrin (FL2)
48 hr of culture at 378C in 5% CO2, nonadherent cells were removed. of the samples, which were generated against the background stain-
Cultures were washed and then maintained in media composed of ing of cells stained with an isotype control antibody (mouse IgG1,
50% spent media/50% fresh media, which was replenished every IgG2a or IgG2b) and the secondary antibody.
3±4 days for up to 90 days poststimulation. Control cell cultures
were established by stimulation of PBMCs from individual donors Restriction Enzyme Analysis of the Reactivated
with Concanavalin A as previously described (Fish et al., 1996). Day HCMV Strains
1 poststimulation is defined as the day after the initial PBMC isola- Cell free viral stocks of the laboratory HCMV strains AD169 and
tion and allogeneic or Con A stimulation. Towne, as well as a clinical isolate obtained from a bone marrow
transplant patient with acute HCMV disease or cell sonicates from
Allo-MDMs from the respective donor pairs, were used to infect HFDetection of HCMV Replication in Allo-MDMs
cultures. DNA was prepared from HF when a cytopathic effect wasfrom Healthy Blood Donors
observed (10±16 weeks for the reactivated strains versus 7±9 daysAllo-MDM cultures were established by mixing PBMCs from two
for the laboratory strains). Ten micrograms of total DNA from unin-healthy blood donors as described above. Samples were collected
fected HF cells was digested with EcoR1 or HindIII, before Southernat day 1, 10, 17, 26, 36, 46, 54, 60, 70, 80, and 90 for detection of
blot analyses using 32P-labeled cosmid clones pCM1058 andHCMV gene products and/or for virus recovery. Sonicated cells were
pCM1049 (Fleckenstein et al., 1982).plated onto HF cells at subconfluency in 96-well plates or in 25 cm2
culture flasks for virus isolation. HF cells in 96-well plates were
Acknowledgmentsincubated for 17±20 days, with feeding every fourth day, and fixed
and stained for the presence of HCMV IE antigens using a polyclonal
We thank Nancy Peffer, David E. Michalik, Heather L. Meyers, Patsyantibody against IE (Fish et al., 1995).
Smith, and Justine Allan Yorke for technical assistance and Drs.For PCR analysis, cell samples were collected at the indicated
Ashlee Moses, Magadeline So, Ann Hill, David Johnson, David Par-time points by scraping. DNA and RNA were prepared using the
ker, and the members of theNelson laboratory for helpful discussion.QIAGEN Blood and the Cell culture DNA kit and RNeasy kit, respec-
We also thank Andrew Townsend for his graphic work. This worktively, according to the manufacturer's instructions. HCMV specific
was supported by a Public Health Service Grant from the Nationalprimer pairs were used in nested RT-PCR reactions detecting IE
Institutes of Health AI 21640 (J. A. N.), the Molecular Hematologyand pp150 RNA (SoÈ derberg et al., 1993). As a positive control for
Training Program NIH NRSA Training Award (K. N. F.), and the Knutthe presence of DNA or RNA, primers detecting glucose-6-phospha-
and Alice Wallenbergs Foundation (C. S.-N.). C. S. -N. is a scholartase dehydrogenase (G6PD) were used for each sample (SoÈ derberg
of the Wenner-Gren Foundation, Sweden.et al., 1993). The primers used for PCR analysis for HCMV IE and
G6PD span an intron and yield different sized bands from amplifica-
Received June 26, 1997; revised August 15, 1997.tion of DNA and RNA, whereas the pp150 gene does not contain
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